Table 2.
Microorganism | Antimicrobial agent | Route | Products approved by the FDA | Date of approval |
---|---|---|---|---|
Methicillin- resistant staphylococcus aureus (MRSA) | Vancomycin | IV | Firvanq® | 2018 |
Vancomycin® | 1999 | |||
Tedizolid | IV/ Oral | Sivextro® | 2014 | |
Daptomycin | IV | Cubicin® | 2003 | |
Linezolid | IV/ Oral | Zyvox® | 2000 | |
Trimethoprim/sulfamethoxazole (+oral Rifampin) |
IV | Sulfamethoxazole and trimethoprim® | 1991 | |
Oral | Sulfamethoxazole and trimethoprim® | 1986 | ||
Clindamycin | IV | Cleocin phosphate® | 1972 | |
Oral | Cleocin hydrochloride ® | 1970 | ||
Methicillin- sensitive staphylococcus aureus (MSSA) | Cefazolin | IV | Cefazolin sodium® | 1988 |
Nafcillin/oxacillin | IV | Unipen® | 1970 | |
P. aeruginosa | Levofloxacin | Oral | Levofloxacin® | 2011 |
IV | Levofloxacin® | 2005 | ||
Ciprofloxacin | IV | Ciprofloxacin® | 2009 | |
Oral | Ciprofloxacin® | 2004 | ||
Meropenem | IV | Merrem® | 1996 | |
Cefepime | IV | Maxipime® | 1996 | |
Piperacillin/tazobactam | IV | Zosyn® | 1993 | |
Ceftazidime | IV | Fortaz® | 1985 | |
Imipenem/cilastin | IV | Primaxin® | 1985 | |
Enterobacteriaceae | Moxifloxacin (+antipseudomonal agents) |
IV/oral | Moxifloxacin hydrochloride® | 2015 |
Ceftriaxone | IV | Cftriaxone® | 2003 | |
Cefotaxime | IV | Cefotaxime sodium® | 2002 | |
Enterobacteriaceae (Anaerobes) |
Clindamycin | IV/oral | Cleocin phosphate® | 1999 |
Cleocin HCL® | 1998 | |||
Metronidazole | Oral | Flagyl® | 1995 | |
IV | Flagyl® | 1981 | ||
Enterococcus spp. (Ampicillin resistant) |
Vancomycin | IV | Firvanq® | 2018 |
Vancomycin® | 1999 | |||
Enterococcus spp. (Ampicillin sensitive) |
Ampicillin/ sulbactam | IV | Unasyn® | 1986 |
Enterococcus spp. (Vancomycin resistant) |
Tedizolid | IV/oral | Sivextro® | 2014 |
Linezolid | IV/ oral | Zyvox® | 2007 | |
Daptomycin | IV | Cubcin® | 2003 | |
Streptococcus spp. | Penicillin G | IV | Bicillin L-A® | 1952 |